StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Legend Biotech Corp. (LEGN)

Thu, 16 Jul 2026 06:48:44 -0400

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $65.00 price target on Legend Biotech Corp. (NASDAQ: LEGN).

The analyst commented: "CARVYKTI $657M 2Q26 print is underappreciated and supports increasingly predictable ramp; in vivo CAR-T remains upside. Sales increased 10% from $597M Q/Q and came 0.3% above consensus of $655.3M. In our view, matching consensus reflects a maturing franchise with quarterly growth that is becoming easier to forecast. First-half sales of $1.254B leave $1.346B needed in 2H26 to reach our ~$2.6B forecast, requiring only a modest step-up from the 2Q run-rate. We continue to see an underappreciated value opportunity

Form 6-K Legend Biotech Corp For: Jul 15

Wed, 15 Jul 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260715/26770892.html

Form 6-K Legend Biotech Corp For: Jul 15

Wed, 15 Jul 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260715/26770892.html

JPMorgan Resumes Legend Biotech Corp. (LEGN) at Neutral

Mon, 13 Jul 2026 03:13:56 -0400

JPMorgan analyst Jessica Fye resumes coverage on Legend Biotech Corp. (NASDAQ: LEGN) with a Neutral rating and a price target of $35.00.

The analyst comments: “We are moving to a Neutral rating on LEGN and establishing a $35 December 2027 price target. Key BCMA CAR-T asset Carvykti has enjoyed a robust launch in multiple myeloma and is still growing, but the market has reasonable concerns about the competitive threat over time from anito-cel, particularly in the 2L-4L setting, and to some extent from the already approved Tec-Dara combo. At the same time, impressive early data for LB2501, dual-targeted CD19/CD20 in vivo

JPMorgan Resumes Legend Biotech Corp. (LEGN) at Neutral

Mon, 13 Jul 2026 03:13:56 -0400

JPMorgan analyst Jessica Fye resumes coverage on Legend Biotech Corp. (NASDAQ: LEGN) with a Neutral rating and a price target of $35.00.

Legend Biotech Corp. (LEGN) PT Lowered to $63 at RBC Capital

Tue, 07 Jul 2026 08:00:14 -0400

RBC Capital analyst Leonid Timashev lowered the price target on Legend Biotech Corp. (NASDAQ: LEGN) to $63.00 (from $64.00) while maintaining a Outperform rating.

Form 4 Legend Biotech Corp For: Jun 30 Filed by: Huang Ying

Thu, 02 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260702/26727564.html

Form 4 Legend Biotech Corp For: Jun 30 Filed by: Huang Ying

Thu, 02 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260702/26727564.html

Form 4 Legend Biotech Corp For: Jun 30 Filed by: Casey Patrick John

Thu, 02 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260702/26727574.html

Form 4 Legend Biotech Corp For: Jun 30 Filed by: Casey Patrick John

Thu, 02 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260702/26727574.html

Form 144 Legend Biotech Corp Filed by: Casey Patrick John

Tue, 30 Jun 2026 10:46:00 -0400

si-local-file:///var/storage/secattach/20260630/26711606.html

Form 144 Legend Biotech Corp Filed by: Casey Patrick John

Tue, 30 Jun 2026 10:46:00 -0400

si-local-file:///var/storage/secattach/20260630/26711606.html

Form 4 Legend Biotech Corp For: Jun 25 Filed by: Huang Ying

Mon, 29 Jun 2026 21:53:00 -0400

si-local-file:///var/storage/secattach/20260629/26708166.html

Form 4 Legend Biotech Corp For: Jun 25 Filed by: Huang Ying

Mon, 29 Jun 2026 21:53:00 -0400

si-local-file:///var/storage/secattach/20260629/26708166.html

Form 144 Legend Biotech Corp Filed by: Huang Ying

Fri, 26 Jun 2026 15:23:00 -0400

si-local-file:///var/storage/secattach/20260626/26698176.html

Form 144 Legend Biotech Corp Filed by: Huang Ying

Fri, 26 Jun 2026 15:23:00 -0400

si-local-file:///var/storage/secattach/20260626/26698176.html

Calidi Biotherapeutics adds biopharma veteran Corsee Sanders to board

Tue, 23 Jun 2026 08:00:36 -0400

Calidi Biotherapeutics, Inc. (NYSE American: CLDI) announced the appointment of Corsee Sanders, Ph.D., to its Board of Directors, effective June 17, 2026, according to a company statement. She will serve as an independent director.

Sanders brings more than three decades of biopharmaceutical experience. She spent 23 years at Genentech/Roche, where she held several leadership roles, including Senior Vice President and Global Head of Clinical Operations and Industry Collaboration for six years.

Following Celgene's acquisition of Juno Therapeutics, Sanders served as strategic advisor to Celgene's Chief Medical Officer. She had previously been Executive Vice President of Development Operations at Juno. She also served

Calidi Biotherapeutics adds biopharma veteran Corsee Sanders to board

Tue, 23 Jun 2026 08:00:36 -0400

Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors

Tue, 23 Jun 2026 08:00:00 -0400

Industry Veteran Brings More Than Three Decades of Biopharmaceutical Development and Clinical Operations Experience to Help Guide Pipeline Advancement

SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced the appointment of Corsee Sanders, Ph.D., to the Board of Directors, effective June 17, 2026. Dr. Sanders, an experienced veteran of the biopharma industry, will serve as an independent director.

“Dr. Sanders has an exceptional track record in developing new technologies,” said Calidi Chairman of the Board Jim Schoeneck. “We

Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors

Tue, 23 Jun 2026 08:00:00 -0400

Industry Veteran Brings More Than Three Decades of Biopharmaceutical Development and Clinical Operations Experience to Help Guide Pipeline Advancement

“Dr. Sanders has an exceptional track record in developing new technologies,” said Calidi Chairman of the Board Jim Schoeneck. “We

Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors

Tue, 23 Jun 2026 08:00:00 -0400

Industry Veteran Brings More Than Three Decades of Biopharmaceutical Development and Clinical Operations Experience to Help Guide Pipeline Advancement

“Dr. Sanders has an exceptional track record in developing new technologies,” said Calidi Chairman of the Board Jim Schoeneck. “We

Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors

Tue, 23 Jun 2026 08:00:00 -0400

Industry Veteran Brings More Than Three Decades of Biopharmaceutical Development and Clinical Operations Experience to Help Guide Pipeline Advancement

“Dr. Sanders has an exceptional track record in developing new technologies,” said Calidi Chairman of the Board Jim Schoeneck. “We

Form 6-K Legend Biotech Corp For: Jun 22

Mon, 22 Jun 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260622/26673401.html

Form 6-K Legend Biotech Corp For: Jun 22

Mon, 22 Jun 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260622/26673401.html

Form 424B5 Legend Biotech Corp

Thu, 18 Jun 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260618/26666704.html